Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

About the trial

Sponsor

Celgene

Tested

Pomalidomide (drug), Dexamethasone (drug), Daratumumab (drug)

Dates

Started 2014-05-29; completion 2025-05-26

Results posted

Yes

This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone (LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of lenalidomide-based therapy. This trial will test the hypothesis for Cohort A that the proportion of patients will have an Overall Response Rate (ORR) of \> 30 % to reveal that Pomalidomide is efficacious in pretreated patients who are refractory to lenalidomide. This trial will test the hypothesis for Cohort B that the proportion of patients …

From ClinicalTrials.gov, last updated 2026-06-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Celgene Corporation reported $21,197 in research payments for this study in 2025 (2 payments).

Products named: Pomalyst

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.